ES2566361T3 - Composiciones y métodos para diagnosticar y/o tratar una infección gripal - Google Patents
Composiciones y métodos para diagnosticar y/o tratar una infección gripal Download PDFInfo
- Publication number
- ES2566361T3 ES2566361T3 ES10794834.1T ES10794834T ES2566361T3 ES 2566361 T3 ES2566361 T3 ES 2566361T3 ES 10794834 T ES10794834 T ES 10794834T ES 2566361 T3 ES2566361 T3 ES 2566361T3
- Authority
- ES
- Spain
- Prior art keywords
- polypeptide
- amino acids
- approximately
- polypeptides
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010022000 influenza Diseases 0.000 title abstract description 27
- 208000015181 infectious disease Diseases 0.000 title description 7
- 238000000034 method Methods 0.000 title description 7
- 239000000203 mixture Substances 0.000 title description 5
- 101710154606 Hemagglutinin Proteins 0.000 abstract description 147
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract description 147
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract description 147
- 101710176177 Protein A56 Proteins 0.000 abstract description 147
- 239000000185 hemagglutinin Substances 0.000 abstract description 147
- 229920001184 polypeptide Polymers 0.000 abstract description 136
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 136
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 136
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 24
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 91
- 150000001413 amino acids Chemical class 0.000 description 79
- 229940024606 amino acid Drugs 0.000 description 78
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 150000004676 glycans Chemical class 0.000 description 24
- 238000006467 substitution reaction Methods 0.000 description 23
- 201000010099 disease Diseases 0.000 description 18
- 239000011230 binding agent Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 238000012217 deletion Methods 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 230000007935 neutral effect Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 238000007792 addition Methods 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 241000271566 Aves Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 102220477627 Aldehyde oxidase_E227H_mutation Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 102200027276 rs267606877 Human genes 0.000 description 4
- 102200162557 rs73507527 Human genes 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102200050586 rs121912427 Human genes 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 101001014213 Homo sapiens Morphogenetic neuropeptide Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102220526795 Methenyltetrahydrofolate cyclohydrolase_D225E_mutation Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102220108595 rs116059308 Human genes 0.000 description 2
- 102220324094 rs1166189035 Human genes 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 108010089814 Plant Lectins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22288909P | 2009-07-02 | 2009-07-02 | |
| US222889P | 2009-07-02 | ||
| PCT/US2010/040978 WO2011003100A2 (en) | 2009-07-02 | 2010-07-02 | Compositions and methods for diagnosing and/or treating influenza infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2566361T3 true ES2566361T3 (es) | 2016-04-12 |
Family
ID=43411785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10794834.1T Active ES2566361T3 (es) | 2009-07-02 | 2010-07-02 | Composiciones y métodos para diagnosticar y/o tratar una infección gripal |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9278998B2 (https=) |
| EP (1) | EP2448596B1 (https=) |
| JP (2) | JP5886194B2 (https=) |
| AU (1) | AU2010266129B2 (https=) |
| CA (1) | CA2766899C (https=) |
| ES (1) | ES2566361T3 (https=) |
| WO (1) | WO2011003100A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9278998B2 (en) | 2009-07-02 | 2016-03-08 | Massachusetts Institute Of Technology | Compositions and methods for diagnosing and/or treating influenza infection |
| WO2011094445A1 (en) * | 2010-01-27 | 2011-08-04 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| WO2012040406A2 (en) | 2010-09-21 | 2012-03-29 | Massachusetts Institute Of Technology | Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines |
| BR112013007946B1 (pt) | 2010-10-04 | 2022-07-12 | Massachusetts Institute Of Technology | Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US10022434B2 (en) | 2013-03-15 | 2018-07-17 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| WO2014179464A1 (en) * | 2013-04-30 | 2014-11-06 | Massachusetts Institute Of Technology | Human adaptation of h3 influenza |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CN109195629A (zh) | 2016-02-24 | 2019-01-11 | 威特拉公司 | 流行性感冒抗体分子制剂 |
| US11781112B2 (en) | 2016-03-06 | 2023-10-10 | Kareem Thomas Robinson | Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| CN113924147A (zh) | 2019-03-25 | 2022-01-11 | 威特拉公司 | 用于治疗和预防流感的组合物和方法 |
| BR112022021208A8 (pt) * | 2020-04-22 | 2023-02-23 | Medicago Inc | Supraestrutura compreendendo hemaglutinina de influenza modificada com interação reduzida com ácido siálico |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4692411A (en) | 1983-09-06 | 1987-09-08 | Ghose Rabindra N | Separation of specific biological cells by a biochemical filter |
| US5698390A (en) | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| US6085349A (en) * | 1997-08-27 | 2000-07-04 | Qualcomm Incorporated | Method for selecting cyclic redundancy check polynomials for linear coded systems |
| JP5008244B2 (ja) | 2000-06-23 | 2012-08-22 | ワイス・ホールディングズ・コーポレイション | 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー |
| US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| WO2006108226A1 (en) | 2005-04-12 | 2006-10-19 | The University Of Queensland | Vaccine delivery system |
| SG169996A1 (en) | 2006-02-16 | 2011-04-29 | Us Gov Health & Human Serv | Antiviral agents and vaccines against influenza |
| US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
| US8778353B2 (en) | 2006-05-01 | 2014-07-15 | Technovax, Inc. | Influenza virus-like particle (VLP) compositions |
| EP1998814A4 (en) | 2006-05-11 | 2010-06-16 | Novavax Inc | NEW VACCINES AGAINST INFLUENZA M2 |
| US9511134B2 (en) * | 2006-05-18 | 2016-12-06 | Epimmune Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| WO2008005777A2 (en) | 2006-06-30 | 2008-01-10 | Novavax, Inc. | Methods of enhancing protein incorporation into virus like particles |
| WO2008094200A2 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| US9439959B2 (en) | 2006-07-27 | 2016-09-13 | Takeda Vaccines, Inc. | Chimeric influenza virus-like particles |
| US20090081193A1 (en) * | 2006-08-14 | 2009-03-26 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| US20080241918A1 (en) * | 2006-08-14 | 2008-10-02 | Ram Sasisekharan | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| US20090269342A1 (en) | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| WO2008040060A1 (en) | 2006-10-04 | 2008-04-10 | The University Of Queensland | Vlp based vaccine delivery system |
| US20080233150A1 (en) | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
| WO2008148104A1 (en) | 2007-05-25 | 2008-12-04 | Novavax, Inc. | Novel vlps derived from cells that do not express a viral matrix or core protein |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| HUE025702T2 (en) | 2007-07-19 | 2016-04-28 | Novavax Inc | Avian Flu Chimeric VLPs |
| CA2711330A1 (en) | 2008-01-03 | 2009-07-16 | Massachusetts Institute Of Technology | Decoy influenza therapies |
| MX370690B (es) | 2008-07-18 | 2019-12-19 | Medicago Inc | Epitopo de inmunizacion de nuevo virus de la influenza. |
| US9278998B2 (en) | 2009-07-02 | 2016-03-08 | Massachusetts Institute Of Technology | Compositions and methods for diagnosing and/or treating influenza infection |
-
2010
- 2010-07-02 US US12/829,931 patent/US9278998B2/en active Active
- 2010-07-02 EP EP10794834.1A patent/EP2448596B1/en active Active
- 2010-07-02 CA CA2766899A patent/CA2766899C/en active Active
- 2010-07-02 AU AU2010266129A patent/AU2010266129B2/en active Active
- 2010-07-02 ES ES10794834.1T patent/ES2566361T3/es active Active
- 2010-07-02 JP JP2012517927A patent/JP5886194B2/ja active Active
- 2010-07-02 WO PCT/US2010/040978 patent/WO2011003100A2/en not_active Ceased
-
2015
- 2015-11-16 JP JP2015224253A patent/JP2016028107A/ja not_active Withdrawn
-
2016
- 2016-01-28 US US15/009,270 patent/US9709567B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2766899C (en) | 2021-05-04 |
| AU2010266129A1 (en) | 2012-02-02 |
| US9709567B2 (en) | 2017-07-18 |
| JP2012532117A (ja) | 2012-12-13 |
| EP2448596A4 (en) | 2013-02-20 |
| US20110033490A1 (en) | 2011-02-10 |
| US20160266117A1 (en) | 2016-09-15 |
| WO2011003100A3 (en) | 2011-02-24 |
| AU2010266129B2 (en) | 2016-04-14 |
| JP2016028107A (ja) | 2016-02-25 |
| WO2011003100A2 (en) | 2011-01-06 |
| JP5886194B2 (ja) | 2016-03-16 |
| EP2448596A2 (en) | 2012-05-09 |
| WO2011003100A4 (en) | 2011-04-14 |
| CA2766899A1 (en) | 2011-01-06 |
| EP2448596B1 (en) | 2016-01-06 |
| US9278998B2 (en) | 2016-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2566361T3 (es) | Composiciones y métodos para diagnosticar y/o tratar una infección gripal | |
| KR101983989B1 (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
| AU2020263900B2 (en) | Recombinant influenza antigens | |
| CN105452270B (zh) | 流行性感冒病毒疫苗及其用途 | |
| CN106661091B (zh) | 流行性感冒病毒疫苗及其用途 | |
| TW201102084A (en) | Methods and compositions for immunization against virus | |
| BR112013007946B1 (pt) | Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina | |
| ES2802623T3 (es) | Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe | |
| AU2011305371B2 (en) | Human-adapted HA polypeptides, vaccines, and influenza treatment | |
| JP6518597B2 (ja) | Ｈ５インフルエンザのヒトへの適応 | |
| PL235555B1 (pl) | Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu | |
| US11426459B2 (en) | Mutant of hemagglutinin protein of H3N2 subtype influenza virus and use thereof | |
| US10526375B2 (en) | Human Adaptation of H7 HA | |
| US20110076297A1 (en) | Peptides for Inducing Heterosubtypic Influenza T Cell Responses | |
| US10195266B2 (en) | Versatile influenza virus vaccine composition | |
| Nuwarda et al. | An Overview of Influenza Viruses and Vaccines. Vaccines 2021, 9, 1032 | |
| JP2012530486A (ja) | インフルエンザウイルスに由来する抗原ペプチド、及び抗インフルエンザウイルス抗体を選択する方法 | |
| RU2757013C2 (ru) | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения | |
| JP2009034061A (ja) | ヒトへの感染力の強いａ型インフルエンザウイルス株の同定方法 | |
| EP4267248A2 (en) | Peptide for use in the treatment or prevention of covid-19 | |
| WO2025231007A1 (en) | Influenza vaccine compositions and methods of making and using same | |
| KR20210114217A (ko) | 범용성 개 인플루엔자 바이러스 백신 조성물 |